Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

By D. Costa, A. Shaw, S. Ou, B. Solomon, Gregory Riely, M. Ahn, Caicun Zhou, S. Shreeve, P. Selaru, A. Polli and 5 more. Journal of Clinical Oncology, 2015

597 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c9ed8a51e46c3c5e90115d56efa18d2b3eb66b0e

Citations in the corpus

• Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. (2016, unknown): “Any cause, in $ 10% Patients Constipation 39 (28) 6 (4) 0 0 45 (33) Fatigue 26 (19) 8 (6) 2 (1) 0 36 (26) Peripheral edema 27 (20) 6 (4) 1 (1) 0 34 (25) Myalgia 25 (18) 5 (4) 1 (1) 0 31 (23) Asthenia 16 (12) 8 (6) 1 (1) 0 25 (18) Headache 16 (12) 4 (3) 2 (1) 0 22 (16) Cough 15 (11) 4 (3) 0 0 19 (14)”